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Background
NK cells contribute to melanoma cell recognition and
anti-tumor immunity, which is traditionally analyzed
using human peripheral blood NK cells. An important
checkpoint in the progression of malignant melanoma is
the metastasis to lymph nodes.
Materials and methods
To investigate the role of lymph node NK cells in disease
progression, we analyzed frequency, phenotype and func-
tions of NK cells purified from either tumor infiltrated
lymph nodes or tumor-free ipsilateral lymph nodes of the
same patients. Lymph node NK cells were compared to
peripheral blood NK cells from either melanoma patients
or healthy donors.
Results
The data showed an expansion of CD56dimCD57+CD69
+CCR7+KIR+ NK cells in tumor infiltrated lymph nodes.
This phenotype corresponds to a recently described fully
mature and highly cytotoxic NK cell population, and
indeed we found that these lymph node NK cells displayed
robust anti-tumor activity against autologous melanoma
cells. The NK cells trafficking from periphery to the tumor
draining lymph nodes have been investigated and the che-
mokines pattern identified. Moreover, the presence of a
high proportion of KIR+CD57+CD56dim in the infiltrated
lymph nodes was associated with an improved patients’
survival.
Conclusions
Our data suggest that NK cells from tumor infiltrated
lymph nodes are attractive candidates to improve current
NK cell-based immunotherapy of melanoma.
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